Zembrin is said to be the world’s first patented, standardized, and clinically studied extract of an elite selection of Sceletium tortuosum.
Zembrin is said to be the world’s first patented, standardized, and clinically studied extract of an elite selection of Sceletium tortuosum. HG&H Pharmaceuticals and its U.S. partner P.L. Thomas introduced Zembrin at SupplySide West as an evidence-based ingredient for products that support reduced anxiety, enhanced mood, and improved cognitive function in a sustained and steady manner.
Sceletium, known by the San people of South Africa as “Kanna,” has been used for millennia for its stress-relieving and mood-enhancing effects, the companies say. The ingredient, which is grown on land P.L. Thomas owns in South Africa, is supported by more than 300 years of indigenous and colonial plant use. The company adds that Zembrin has been awarded the first ever Export and Bioprospecting permit to be issued by the South African Government.
The ingredient is self-affirmed GRAS and has an alkaloid content ranging from 0.05-2.3%. The company says that the first efficacy trial on the ingredient was successful, with additional efficacy trials now underway.
"Zembrin is a unique opportunity-a unique, experiential and rapidly acting botanical extract," the company states. "You actually 'feel' its benefits and experience enhanced mood and concentration and relief from stress."